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Abstract
Background: Dyscarbia is common in out-of-hospital cardiac arrest (OHCA) patients and its association to
neurological outcome is undetermined.
Methods: This is an exploratory post-hoc substudy of the Target Temperature Management (TTM) trial, including
resuscitated OHCA patients, investigating the association between serial measurements of arterial partial carbon
dioxide pressure (PaCO2) and neurological outcome at 6 months, defined by the Cerebral Performance Category
(CPC) scale, dichotomized to good outcome (CPC 1 and 2) and poor outcome (CPC 3–5). The effects of hypercapnia
and hypocapnia, and the time-weighted mean PaCO2 and absolute PaCO2 difference were analyzed. Additionally, the
association between mild hypercapnia (6.0–7.30 kPa) and neurological outcome, its interaction with target temperature
(33 °C and 36 °C), and the association between PaCO2 and peak serum-Tau were evaluated.
Results: Of the 939 patients in the TTM trial, 869 were eligible for analysis. Ninety-six percent of patients were exposed
to hypocapnia or hypercapnia. None of the analyses indicated a statistical significant association between PaCO2 and
neurological outcome (P = 0.13–0.96). Mild hypercapnia was not associated with neurological outcome (P = 0.78) and
there was no statistically significant interaction with target temperature (Pinteraction = 0.95). There was no association
between PaCO2 and peak serum-Tau levels 48 or 72 h after return of spontaneous circulation (ROSC).
Conclusions: Dyscarbia is common after ROSC. No statistically significant association between PaCO2 in the
post-cardiac arrest phase and neurological outcome at 6 months after cardiac arrest was detected. There was
no significant interaction between mild hypercapnia and temperature in relation to neurological outcome.
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Background
Out-of-hospital cardiac arrest (OHCA) is a common rea-
son for critical care admission [1–3]. Despite increasing
survival after OHCA with initial shockable rhythm in
the last decades [4, 5], overall survival is still low [6, 7],
and brain injury continues to be the principal cause of
death and disability [5, 8]. Guidelines recommend venti-
lation to normal carbon dioxide levels after return of
spontaneous circulation (ROSC) [9, 10]. However, unin-
tended hyperventilation during and after resuscitation
frequently occurs and variability in ventilation leading to
dyscarbia is a prevalent finding in the post-cardiac arrest
phase [11, 12]. Elevated arterial carbon dioxide partial
pressure (PaCO2), hypercapnia, may lead to cerebral
vasodilatation and increased cerebral blood flow (CBF),
while a decrease in PaCO2, hypocapnia, can exert the
opposite effect [13]. PaCO2 is also a central variable in
acid–base homeostasis encompassing hypercapnic acid-
osis or hypocapnic alkalosis [14]. In recent studies, PaCO2
was associated with neurological outcome after OHCA;
hypocapnia was related to poor neurological outcome
[15–17], whilst hypercapnia was associated with good as
well as poor neurological outcome [16–21].
As hypercapnia has been associated with good neuro-
logical outcome [16], the novel concept of targeted
therapeutic mild hypercapnia (TTMH) has been tested
in the pilot randomized Carbon Control and Cardiac
Arrest (CCC) trial and shown to be safe, feasible to
perform, to lower biomarkers of brain damage, and to
have a tendency for improved global functional outcome
[21]. A phase III randomized clinical trial has recently
started recruiting patients to further investigate the impact
of TTMH on neurological outcome (ClinicalTrials.gov
NCT03114033) and there are active plans to coenroll
patients with the ongoing TTM2 trial (ClinicalTrials.gov
NCT02908308) comparing hypothermia to normothermia
after cardiac arrest [22].
We conducted this exploratory substudy of the TTM
trial to describe the evolution of PaCO2 in serial measure-
ments at predefined time points during the first hours after
ROSC, to explore the role that PaCO2 may have in the
neurological outcome of OHCA patients, and to specific-
ally analyze the interaction between mild hypercapnia and
targeted temperature management in relation to neuro-
logical outcome. To further strengthen the analyses, we
investigated the association of PaCO2 to a surrogate
marker of neurological outcome: peak levels of serum-
protein Tau, a marker of neuronal damage that has shown
to be more accurate than neuron specific enolase (NSE) in
predicting outcome [23].
Methods
This study is based on the TTM trial conducted between
2010 and 2013 and was approved by the TTM trial
steering group before completion of the trial [24]. Ethical
committees in each participating country approved the
TTM trial protocol and informed consent was waived or
obtained according to national legislations, in line with
the Helsinki declaration. The patients included were
unconscious (GCS < 8) adults (≥ 18 years of age) with
stable ROSC after OHCA of presumed cardiac cause.
The main exclusion criteria were unwitnessed cardiac
arrest with asystole as the primary rhythm, known or
suspected intracranial hemorrhage or stroke, and time
from ROSC to screening > 240 min [24]. All patients were
admitted to an intensive care unit (ICU), intubated,
sedated, and mechanically ventilated. After inclusion, the
patients were randomized to the 33 °C group or the 36 °C
group and the temperature controlled during the inter-
vention period of 36 h, which commenced at inclusion
into the trial. Mandatory sedation was discontinued 36 h
after inclusion. The TTM study analyzed 939 eligible
patients with no difference in survival or neurological
outcome at 6 months between the two allocation groups
[24]. For this substudy we included patients surviving the
intervention period in order to have a defined exposure
period for carbon dioxide.
Patient data and blood sampling
Prehospital data were reported according to the Utstein
criteria [25]. Baseline, intervention-related, and physio-
logical variables, comorbidities, demographic, prehospital,
and admission data, as well as characteristics of the
cardiac arrest and baseline laboratory analyses were
collected. A complete arterial blood gas analysis was
performed in all patients at admission to the hospital,
at the start of the intervention (T0, which also was the
time of randomization), and after 4, 12, 20, 28, 32, and
36 h. All arterial blood gases were managed according
to the alpha-stat method. The median time from ROSC
to randomization was 133 (interquartile range 83–188)
min. To include the admission blood gas (after ROSC,
but before randomization) we timed this PaCO2 value
to 1 h before T0 (T – 1). PaCO2 data were surveyed for
physiological plausibility and in four of the measurements
we corrected a misplaced decimal point. Corrections were
conducted by FE and NN in accordance with other data
registered on the same patient.
Outcome
The primary outcome was overall neurological function
at 6-month follow-up, using the Cerebral Performance
Category (CPC) scale (CPC 1 = good cerebral perform-
ance; CPC 2 = moderate cerebral disability, independent
in activities of daily life; CPC 3 = severe cerebral disability,
dependent on others for daily support; CPC 4 = vegetative
state; and CPC 5 = dead) [26–28]. The CPC scale was
dichotomized to good (CPC 1 and 2) and poor (CPC 3–5)
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outcome [29]. In a secondary analysis we used the
biomarker protein Tau as the outcome to strengthen
the analyses using neurologic functional outcome.
Main analysis
Levels of carbon dioxide
As our main analysis, we studied the association of dyscarbia
with neurological outcome by dividing the cohort into three
groups according to the single highest or lowest PaCO2
value during the observation period. The groups were
defined as hypocapnia (< 4.5 kPa), normocapnia (4.5–
6.0 kPa), and hypercapnia (> 6.0 kPa) in keeping with a
previous investigation [16]. The outcomes of the hyper-
capnia and hypocapnia groups were each compared with
the normocapnia group. Then, we compared the outcome
of the hypercapnia and hypocapnia groups with the out-
come of a compound group of the remaining patients.
Secondary analyses
Carbon dioxide amplitude
The amplitude in PaCO2 (ΔPaCO2) was calculated as a
continuous variable, investigating an association of max-
imum amplitude in PaCO2 during the observation period
and neurological outcome.
Carbon dioxide over time
We obtained an approximation of the time-weighted
mean carbon dioxide exposure as an area under the
curve (AUC) by integrating PaCO2 over time. The AUC
including eight PaCO2 values was analyzed, investigating
an association with neurological outcome over the whole
observation period, as well as the AUC of the first four
PaCO2 values, in order to study the influence of early
dyscarbia. To investigate nonlinear patterns, we divided
the PaCO2 AUC for the whole exposure time into
quintiles.
Maximum PaCO2 and lowest pH analysis
The association between maximum PaCO2 and lowest
pH as continuous variables and neurological outcome was
evaluated in univariable analyses. Thereafter, both vari-
ables were introduced into a combined logistic regression
model.
Therapeutic targeted mild hypercapnia
From the time-weighted mean carbon dioxide exposure
analysis, we extracted two PaCO2 groups approximating
the PaCO2 ranges employed by Eastwood et al. [21]
(4.5–6.0 kPa and 6.0–7.30 kPa) and subdivided them
according to target temperature (33 °C and 36 °C) in
order to detect possible interactions between PaCO2 and
temperature in relation to outcome.
Analyses using a biomarker as outcome
Association of PaCO2 and s-Tau
A nested cohort analysis was performed in 689 patients
in a previous substudy of the TTM trial, evaluating
s-Tau levels at 24, 48, and 72 h after ROSC, showing the
highest accuracy of predicting poor outcome after
6 months for peak s-Tau at 48 and 72 h [23]. Therefore,
we analyzed the association of PaCO2 and peak s-Tau at
these time points, employing the multivariable models
used for our primary analyses.
Sensitivity analyses
For sensitivity analysis we used the complete case cohort
consisting of 485 patients (56%) with blood gas samples
registered from all measuring points and the total case
(n = 939) cohort including 100% of the patients, even
those not surviving the full exposure period.
Statistical considerations
Proportions are expressed as percentages and continuous
data as means with standard deviations (SDs). The
association between PaCO2 and neurological outcome
was analyzed using logistic regression. Except for the
maximum PaCO2 and lowest pH analyses, all analyses
were corrected for prespecified and relevant covariates:
age (years), sex (male/female), chronic heart failure
(yes/no), asthma/chronic obstructive pulmonary disease
(yes/no), cardiac arrest witnessed (yes/no), bystander
CPR (yes/no), first rhythm shockable (yes/no), time to
ROSC (minutes), GCS-Motor score (1 versus 2–5),
shock on admission (yes/no), and pH at admission
(units). Whether pooling of the two temperature groups
was feasible was established by a term of interaction
model between the PaCO2 analysis groups and the two
temperature groups. A significant term of interaction
entailed subgroup analyses for the 33 °C and the 36 °C
groups. A nonsignificant term of interaction entailed a
combined group analysis.
Logistic regressions are presented as odds ratios (ORs)
with 95% confidence intervals (CIs), with OR below 1
indicating better and OR above 1 indicating worse
neurological outcome. ORs relating to continuous data
describe the variation per one unit (1 kPa for PaCO2
and 1 unit for pH).
For s-Tau analysis, multivariable linear regression was
used including the same covariables and interaction ana-
lyses as already described. s-Tau values where transformed
to a logarithmic scale and used as outcome in the linear
regression analyses. The regression coefficients achieved
for each independent variable were transformed back and
reflect the multiplicative change in s-Tau. This means that
coefficients below 1 correspond to a decrease in s-Tau and
coefficients above 1 to an increase. Linear regressions are
presented as coefficient estimates with 95% CI.
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Multiple imputation was used to compensate for missing
values. We employed predictive mean matching, where
information from nonmissing values of the same indi-
vidual, all available TTM trial study variables, and
values of matching patients were used to impute the
missing values. In total, 20 imputed datasets were generated
by chained equations and evaluated by graphical methods.
The summary measures of PaCO2 (e.g., hypocapnia, hyper-
capnia, range) where computed for each imputed dataset
and evaluated using regression models. The estimates from
the logistic and linear regression for each imputed sample
were combined into one estimate with 95% CI including
the uncertainty from the multiple imputations based on
Rubin’s rule [30]. The primary analyses were performed
on a multiple imputation cohort. A complete case
cohort was used for sensitivity analysis. We regarded
two-sided P < 0.05 as significant. Analyses were conducted
using IBM SPSS statistics for Windows version 22.0
(Armonk, NY, USA) and R: A language and environment
for statistical Computing version 3.3.3 (R Foundation for
Statistical Computing, Vienna, Austria), with the package
mice used for multiple imputations [31].
Results
From the 939 patients included in the TTM trial we
excluded patients who did not survive the analysis
period (n = 62), patients with no PaCO2 data (n = 2), and
patients with no data on neurological outcome (n = 6)
(Fig. 1), leaving 869 (93%) patients for analysis. Additional
data on the number of excluded patients at each measuring
point are presented in Additional file 1: Table S1. Baseline
characteristics of the included patients are presented in
Table 1. Of 6952 analyzed measuring points, 878 (12.6%)
were missing. Detailed information regarding the number
of missing values at each time point is presented in Table 2
and multiple imputation was used to overcome the
missingness. In total, 485 patients had no missing
values. Overall, 440 (50.6%) of 869 patients had a good
outcome while the outcome of 429 (49.4%) patients was
considered poor.
On arrival, the mean PaCO2 was 6.40 (SD 1.99) kPa
and decreased over time in both the temperature and
outcome groups (Fig. 2). In total, 516 of 869 (59%) pa-
tients were hypocapnic and 685 of 869 (79%) patients
were hypercapnic at some time point during the analysis
period; 371 (43%) patients were both hypocapnic and
hypercapnic, and only 39 (4%) patients were normocapnic
throughout. Six-month outcome data of the exposure
groups are presented in Additional file 1: Table S2. The
ΔPaCO2 group had a mean range of 2.88 (SD 1.60) kPa.
The PaCO2 AUC for the first four measuring points was
mean 5.51 (SD 0.92) kPa while the PaCO2 AUC for all
measurements was mean 5.37 (SD 0.62) kPa.
The analysis of interaction between temperature groups
(33 °C or 36 °C) and PaCO2 groups showed no significant
difference for the main outcome (Pmain outcome = 0.072–0.98)
in all comparisons. The terms of interaction, except for
ΔPaCO2 (P = 0.046), were also nonsignificant (Pinteraction =
0.255–0.947). For the ΔPaCO2 group, the 33 °C and the
36 °C subgroups were analyzed separately, showing no
significant association with outcome in any of the groups
which made pooling of temperature groups feasible.
Fig. 1 Patient selection pathway for the PaCO2 outcome analyses. TTM 33/TTM 36 TTM group at 33 °C/36 °C core body temperature derived
from TTM trial study [24]. Selection pathway for s-Tau analysis or sensitivity analyses not shown. TTM target temperature management, n number
of patients, PaCO2 partial carbon dioxide pressure
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Multivariable models with all covariables included in
the analyses for hypercapnia and hypocapnia versus
normocapnia are presented in Tables 3 and 4.
Our main analysis revealed no statistically significant
difference between the hypercapnia and normocapnia
groups (OR 0.70, 95% CI 0.44–1.11; P = 0.13) or the
hypercapnia and nonhypercapnia groups (OR 0.80, 95%
CI 0.51–1.22; P = 0.31) in relation to poor neurological
outcome. In a similar analysis, the hypocapnia group was
compared to the normocapnia group and subsequently to
the nonhypocapnia group with no significant differences
(OR 0.96, 95% CI 0.64–1.45; P = 0.85 and OR 1.04, 95%
CI 0.72–1.49; P = 0.82, respectively). The ΔPaCO2 analysis
did not reveal a statistically significant association with poor
neurological outcome, either for the 33 °C or the 36 °C
subgroup (OR 1.08, 95% CI 0.9–1.29; P = 0.37 and OR 1.00,
95% CI 0.82–1.20; P = 0.96, respectively), or for the
combined group (OR 1.04, 95% CI 0.91–1.18; P = 0.56).
The PaCO2 AUC from admission to the end of intervention
time and for the first four measured PaCO2 values
(early dyscarbia) was not associated with poor neuro-
logical outcome (OR 1.09, 95% CI 0.83–1.42; P = 0.53
and OR 0.99, 95% CI 0.81–1.22; P = 0.96, respectively).
Furthermore, we were not able to detect an association
pattern with neurological outcome after we divided the
total exposure time PaCO2 AUC into quintiles (P =
0.73–0.96). Details of this investigation are presented in
Additional file 1: Table S5.
When analyzed separately in univariable logistic regres-
sion models, maximum PaCO2 as well as lowest pH
showed highly significant associations with poor neuro-
logical outcome (OR 1.17, 95% CI 1.06–1.28; P < 0.001
and 0.03, 95% CI 0.01–0.09; P < 0.001, respectively). When
analyzed in a combined logistic regression model, only
the significant association between lowest pH and poor
neurological outcome prevailed (OR 0.02, 95% CI 0.05–
0.11; P < 0.001) per unit decrease in pH, while PaCO2
lost its significant association with neurological outcome
(OR 0.97, 95% CI 0.86–1.09; P = 0.62). PaCO2 and pH
were not highly correlated with a collinearity between the
regression coefficients of − 0.64.
The TTMH analysis, comparing a normocapnia group
to a mild hypercapnia group, showed a nonsignificant
term of interaction (P = 0.79) between temperature and
PaCO2 in relation to outcome; thus, we continued with
a multivariable model without interaction. This analysis
did not show a significant difference either between the
mildly elevated (n = 121) and normocapnic (n = 675) PaCO2
groups (OR 1.01, 95% CI 0.60–1.67; P = 0.98) in relation to
neurological outcome or between the temperature groups
(OR 0.96, 95% CI 0.68–1.35; P = 0.83).
Of the 689 patients in the s-Tau nested cohort analysis,
100 were excluded either due to our exclusion criteria (n =
64) or missing peak s-Tau values (n = 36). The multivari-
able analysis of the remaining 589 patients showed no
association between PaCO2 and s-Tau in our models
(P = 0.12–1.00). The terms of interaction analysis were
nonsignificant (Pinteraction = 0.11–0.83). Complete results
are presented in Table 5.
Both sensitivity analyses revealed similar results as the
analyses on the imputed dataset, for the complete sample
cohort with 485 patients (P = 0.32–0.96) and for the
all-patient cohort with 939 patients (P = 0.15–0.98). For
Table 1 Patient baseline characteristics
Demographic characteristic Total n = 869
Age (years), mean ± SD 63.9 ± 12.2
Male sex, n (%) 707 (81.4)
Background, n (%)
Chronic heart failure 55 (6.3)
TIA or stroke 69 (8.0)
Arterial hypertension 347 (40.1)
Asthma/COPD 86 (9.9)
Diabetes mellitus 128 (14.8)
Previous PCI 101 (11.6)
Previous CABG 82 (9.5)
Cardiac arrest characteristics
Bystander witnessed arrest, n (%) 783 (90.1)
Bystander CPR, n (%) 638 (73.4)
Shock on admission, n (%) 111 (12.8)
Prehospital intubation, n (%) 576 (67.2)
Time to ROSC (min), mean ± SD 30.4 ± 21.7
Characteristics on admission
pH 7.21 ± 0.15
PaCO2 (kPa), mean ± SD 6.4 ± 2
PaO2 (kPa), mean ± SD 25.1 ± 17
Lactate (mmol/L), mean ± SD 6.5 ± 4.3
BE -5 or less (mmol/l), n (%) 579 (7.3)
GCS-Motor score 1, n (%) 443 (51.3)
Sedated on arrival, n (%) 254 (29.4)
SD standard deviation, TIA transient ischemic attack, COPD chronic obstructive
pulmonary disease, PCI percutaneous coronary intervention, CABG coronary
artery bypass graft, CPR cardiopulmonary resuscitation, ROSC return of
spontaneous circulation, PaCO2 arterial carbon dioxide pressure, PaO2 arterial
oxygen pressure, kPa kilopascal, BE base excess, GCS Glasgow Coma Scale
Table 2 Number of missing measurements at each time point.
Time (h)
T − 1a 0 4 12 20 28 32 36
Missing n 45 154 94 91 118 117 135 124
% of total 5.18 17.7 10.8 10.4 13.6 13.5 15.5 14.2
Total n = 869
aTime at admission, after return of spontaneous circulation but
before randomization
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details concerning the sensitivity analyses, see Additional
file 1: Tables S3 and S4.
Discussion
In this exploratory substudy of the TTM trial, dyscarbia
after ROSC was frequent. We were not able to detect a
statistically significant association between hypercapnia,
hypocapnia, PaCO2 AUC, or ΔPaCO2 and neurological
outcome. There was no significant interaction between
temperature group and carbon dioxide level in relation
to outcome. PaCO2 was not associated with peak s-Tau
levels 48 or 72 h after randomization.
Fig. 2 Distributional characteristics of PaCO2 over time. Distributional characteristics of PaCO2 at eight measurement points from admission to
hospital to end of intervention at 36 h for TTM 33 and TTM 36 groups and investigated combined cohort dichotomized into good and poor
outcome. Boxplot values displayed as median, 25% quartiles from median, and range. Core body temperature 33 °C or 36 °C. PaCO2 arterial
carbon dioxide pressure, kPa kilopascal.
Table 3 Multivariate model of hypercapnia versus normocapnia
in relation to neurological outcome
OR 95% CI P value
Hypercapnia (normocapnia reference) 0.70 0.44–1.11 0.13
TTM group (33 °C reference) 1.00 0.71–1.42 0.99
Age (per year) 1.07 1.05–1.08 < 0.001
Sex (male reference) 1.34 0.84–2.15 0.22
Chronic heart failure (yes/no) 2.09 0.98–4.46 0.06
Asthma/COPD (yes/no) 1.32 0.72–2.43 0.37
Bystander witnessed arrest (yes/no) 0.61 0.35–1.07 0.09
Bystander CPR (yes/no) 0.87 0.57–1.33 0.53
Time to ROSC (per min) 1.03 1.02–1.04 < 0.001
GCS-Motor score (1 vs 2–5) 2.5 1.72–3.57 < 0.001
Shock on admission (yes/no) 1.56 0.88–2.75 0.13
First rhythm shockable (yes/no) 0.19 0.11–0.33 < 0.001
pH (per 1.0 unit increase) 0.28 0.07–1.17 0.08
Hypercapnia = PaCO2 > 6.0 kPa, normocapnia = PaCO2
4.5–6.0 kPa, hypocapnia = PaCO2 < 4.5 kPa
OR < 1 indicates better outcome OR odds ratio, CI confidence interval, TTM
Target Temperature Management, COPD chronic obstructive pulmonary
disease, CPR cardiopulmonary resuscitation, ROSC return of spontaneous
circulation, GCS Glasgow Coma Scale
Table 4 Multivariate model of hypocapnia versus normocapnia
in relation to neurological outcome
OR 95% CI P value
Hypocapnia (normocapnia reference) 0.96 0.64–1.45 0.85
TTM group (33 °C reference) 1.00 0.69–1.46 0.99
Age (per year) 1.06 1.04–1.08 < 0.001
Sex (male reference) 1.58 0.95–2.63 0.08
Chronic heart failure (yes/no) 1.95 0.87–4.37 0.10
Asthma/COPD (yes/no) 1.41 0.74–2.66 0.29
Bystander witnessed arrest (yes/no) 0.55 0.29–1.05 0.07
Bystander CPR (yes/no) 0.97 0.62–1.53 0.91
Time to ROSC (per min) 1.03 1.02–1.05 < 0.001
GCS-Motor score (1 vs 2–5) 1.92 1.32–2.86 0.001
Shock on admission (yes/no) 2.4 1.33–4.34 0.004
First rhythm shockable (yes/no) 0.16 0.09–0.29 < 0.001
pH (per 1.0 unit increase) 0.22 0.05–0.89 0.03
Hypercapnia = PaCO2 > 6.0 kPa, normocapnia = PaCO2
4.5–6.0 kPa, hypocapnia = PaCO2 < 4.5 kPa
OR < 1 indicates better outcome
OR odds ratio, CI confidence interval, TTM Target Temperature Management,
COPD chronic obstructive pulmonary disease, CPR cardiopulmonary
resuscitation, ROSC return of spontaneous circulation, GCS Glasgow Coma
Scale, PaCO2 arterial carbon dioxide pressure
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Our results differ from a prospective single-center
study by Roberts et al. [17] including 193 post-cardiac
arrest patients, suggesting an independent association
between hypocapnia and hypercapnia and poor neuro-
logical function at hospital discharge. In contrast to our
study, Roberts et al. [17] included mainly patients after
in-hospital cardiac arrest and used TTM in six patients
only. Dyscarbia was less common compared to the
present study (69% versus 96%). Our results also differ
from a database study by Schneider et al. [16] analyzing
PaCO2 values of 16,542 patients admitted after cardiac
arrest that showed a higher likelihood of discharge home
for the group of patients exposed to hypercapnia after
ROSC compared to normocapnia or hypocapnia. As in
our study, dyscarbia after ROSC was common. However,
important confounders on background information on
the nature of cardiac arrest (initial rhythm, time to
ROSC, etc.) were not available and, apart from a nested
cohort analysis, only single PaCO2 values were analyzed.
With the exception of the CCC trial [21] randomizing to
different targets of PaCO2, we are aware of only one
study analyzing multiple PaCO2 values over time during
the post-cardiac arrest phase [20]. This prospective obser-
vational study, including 409 OHCA patients analyzed
serial blood gases during the first 24 h after ROSC and
found that exposure to a moderately increased PaCO2
level was an independent predictor for good outcome at
12 months. We chose a comparable approach in our
analysis of the PaCO2 AUC, but could not confirm this
finding. In their study, blood gases were analyzed by either
alpha-stat or pH-stat [20], while the blood gas manage-
ment method employed in our study was exclusively
alpha-stat. The solubility of carbon dioxide in blood is
temperature dependent and might influence the ventila-
tion strategy. Ventilation has, via the coupling of carbon
dioxide and cerebral vascular tone, influence on CBF in
OHCA patients treated with TTM [32]. Voicu et al. [32]
showed a significant difference in PaCO2, arterial pH, and
CBF when alpha-stat was compared to pH-stat. These
findings might identify a source of error in studies using
mixed blood gas management [33] and when comparing
studies using different methods, which might explain
the deviance of our results from other studies. pH in
our study was independently associated with neurological
outcome whereas maximum PaCO2 was not. This
confirms previous findings that pH is an independent
outcome predictor after ROSC [34, 35].
Our study does not indicate benefit of TTMH as
investigated by Eastwood et al. [21], but also no harm. It
is imperative to appreciate that we, in contrast to the
pilot CCC trial [21], compared time-weighted mean
PaCO2 values (observed, nontargeted PaCO2), while the
CCC trial randomized patients to specific PaCO2 ranges
(prescribed, targeted PaCO2). Additionally, we widened
the mild hypercapnia group for our analysis to 6.0–7.30 kPa
for increased robustness of our results. Whether TTMH is
indeed beneficial remains to be proven in a definitive
clinical trial [21]. Importantly, there was no significant
interaction between temperature level and PaCO2 in terms
of outcome, supporting the possibility to coenroll in trials
investigating carbon dioxide and temperature targets [22].
The effects of PaCO2 on biomarkers have to date only
been evaluated in the aforementioned CCC trial where
mild hypercapnia reduced NSE and S100 calcium-binding
protein B (S100B) levels [21]. In our cohort, PaCO2
showed no association with peak s-Tau levels, which is in
line with the lack of association between PaCO2 and
neurological outcome in our study. We have previously
reported that s-Tau is superior to NSE in predicting
outcome and that S100 does not add to a prediction
model including NSE and clinical information [23, 36].
Study strengths and limitations
There is no consensus on how to report carbon dioxide
levels in relation to outcome in cardiac arrest patients
and previous studies have employed methods suited to the
nature of their data (single lowest/highest values versus
serial measurements, within a defined time period versus
not, using a prespecified sampling plan or not). In this
study we have employed many different analytic
approaches and used different outcomes (functional
outcome and biomarkers) in order to provide an investiga-
tion as robust as possible. It is important to emphasize
that the study was conceived post hoc and with a definite
exploratory approach. All results must be regarded as
hypothesis generating, and due to the observational design
we cannot make causality statements. Blood gases repre-
sent the PaCO2 at a certain point in time and we assumed
that the PaCO2 between blood samples was linear. It is
Table 5 Results of peak s-Tau nested cohort analysis for the
employed multivariable models
Multivariable model Estimate 95% CI P value
Hypocapnia vs nonhypocapniaa 1.07 0.73–1.57 0.71
Hypocapnia vs normocapniaa 1.37 0.45–4.15 0.57
Hypercapnia vs nonhypercapniaa 0.68 0.42–1.10 0.12
Hypercapnia vs normocapniaa 1.00 0.38–2.64 1.00
Amplitudeb 1.04 0.91–1.20 0.53
AUC, all valuesb 1.08 0.83–1.42 0.56
AUC, first four valuesb 0.94 0.76–1.17 0.59
TTMH Mild hypercapnia vs normocapniaa 0.75 0.43–1.28 0.29
s-Tau serum Tau, CI confidence interval, AUC area under curve,
TTMH therapeutic targeted mild hypercapnia
aFor analyses of categorical data, estimate indicates how many times higher
s-Tau is compared to reference group
bFor analyses of continuous data, estimate indicates how much higher s-Tau is
per 1 kPa arterial carbon dioxide pressure increase
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also important to point out that patients not surviving the
analysis period were excluded from the analysis to allow a
defined exposure period of carbon dioxide. Our data were
corrected for strong covariables available at admission to
hospital and no covariables that may have been available
later during hospital stay; therefore we did not include, for
example, PaO2 as a covariable in our analyses. There are,
however, considerable strengths in our analysis as data
were derived from a large, well-controlled cohort of OHCA
patients with availability of important confounders. Physio-
logical and biochemical data were collected prospectively
at specified time points according to a predefined protocol
and blood gases were analyzed in a uniform way. Measure-
ments were serial and therefore likely to demonstrate the
association of PaCO2 with outcome in the post-cardiac
arrest phase more accurately than single measurements.
Follow-up data were acquired with face-to-face interviews
using a structured protocol and the loss of patients in
the follow-up period was minimal [24]. We performed
sensitivity analyses of patients with all data registered at
all sampling points and including all patients, even those
not surviving the full analysis period, and obtained similar
results.
Conclusion
Dyscarbia after ROSC was common in OHCA patients,
but PaCO2 measured as extreme values and over time
was not associated with neurological outcome at 6-month
follow-up. Mild hypercapnia was not associated with adverse
outcome and there was no interaction with temperature
group affiliation.
Additional file
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